Olutasidenib drug interaction study for IDH1 mutation cancers
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests how olutasidenib interacts with other drugs in people with cancers that have an IDH1 mutation, like certain leukemias or brain tumors. Participation may help determine the best way to take this treatment safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older with a cancer that has an IDH1 mutation (like acute myeloid leukemia, colorectal cancer, or glioma).
- You should be well enough to perform daily activities (ECOG performance status 0-2).
- Your liver and kidney function must meet specific lab test values.
- You must not have had olutasidenib within 2 weeks of starting the study.
- You cannot be pregnant or breastfeeding, and must use effective birth control if applicable.
- You must not smoke actively or drink alcohol within 72 hours of starting the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests safusidenib, a targeted medicine, to help stop or slow the return of certain brain tumors with an IDH1 mutation. It focuses on people after initial treatment (surgery and/or radiation and temozolomide), aiming to improve outcomes during maintenance therapy.
This trial tests a drug called olutasidenib for people with certain blood cancers (AML, MDS, or CMML) that have a specific IDH1 gene change. The goal is to see if it can help prevent relapse after a donor stem cell transplant.
This trial tests a drug called olutasidenib, either alone or with other treatments, to see if it can help keep your AML in remission after you've finished your first round of therapy. It's for people whose AML has a specific change in the IDH1 gene.
This trial tests an oral drug called olutasidenib in people with certain low-risk blood cancers or a pre-cancer condition. It may help by targeting a specific genetic change (IDH1 mutation) found in your blood cells.
This trial tests a targeted drug, olutasidenib, for people with AML or MDS whose cancer cells have an IDH1-R132 mutation. Depending on your specific diagnosis, you may receive olutasidenib alone or combined with other medicines.
This trial tests a combination of olutasidenib with other targeted drugs for people with certain blood cancers that have returned or not responded to treatment. It focuses on patients who have both an IDH1 mutation and a second activating mutation in specific signaling genes.
Hear when a new Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.